C5a Receptor Antagonism Shows Steroid-Sparing Effect in Vasculitis

The management of autoimmune rheumatic diseases has long been hampered by a significant gap between clinical guidelines and real-world practice, where fewer than half of patients achieve sustained remission [1]. While traditional therapies often rely on broad immunosuppression, the focus has shifted toward identifying specific signaling pathways that drive tissue damage and chronic inflammation [2, 3]. The complement system, a critical component of innate immunity, is increasingly recognized as a central mediator of this pathology, particularly through its role in orchestrating leucocyte infiltration and vascular injury [4, 5]. However, the clinical application of complement inhibitors remains complex, as the therapeutic window and specific pathway targets vary significantly across different autoimmune phenotypes [4, 1]. A new analysis now clarifies how targeting specific components of this system may redefine treatment protocols for some of the most challenging inflammatory conditions.